A Novel and Efficient Synthesis of a Highly Active Analogue of clasto-Lactacystin β-Lactone
Citations Over TimeTop 10% of 1999 papers
Abstract
Herein, we describe a new convergent synthesis of a more potent analogue of clasto-lactacystin β-lactone (2), PS-519 compound 4, which is currently in preclinical development for the treatment of ischemia−reperfusion injury in stroke and myocardial infarction. The synthetic strategy relies on building two intermediates (an oxazoline and an aldehyde) which are joined through a doubly diastereoselective aldol reaction, setting up the requisite unichiral centers in the final product (4). The facial selectivity and ultimate stereocontrol are achieved by employing a trivalent aluminum Lewis acid, Me2AlCl, in a chelation-induced reaction which yields a single aldol adduct. The efficiency of the synthetic approach has allowed for the preparation of multigram quantities of clinical grade material, which will support Phase I studies.
Related Papers
- → Novel poly(2-oxazoline)s with pendant l-prolinamide moieties as efficient organocatalysts for direct asymmetric aldol reaction(2016)12 cited
- → First Catalytic Aldol-Transfer Reaction via Aluminum Enolates: A New Way To Generate Aldol Adducts of Aldehydes from Aldol Adducts of Ketones(2000)30 cited
- → Studies in Organocatalysts Synthesis for Direct Aldol Reaction(2013)
- → Novel Lewis Acid ATNP for Vinylogous Aldol Reactions(2012)
- → Boron Lewis Acids(2009)